Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for APLS

Stock NameApellis Pharmaceuticals Inc
TickerAPLS(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS03753U1060
LEI254900HS0ZFRXXSB9D42

Show aggregate APLS holdings

News associated with APLS

Short Interest in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Grows By 34.0%
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 22,090,000 shares, agrowthof34.0% from the July 15th total of 16,490,000 shares. Based on an average daily volume of 2,450,000 shares, the days-to-cover ratio […] - 2025-08-22 05:26:48
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock Holdings Lessened by Deutsche Bank AG
Deutsche Bank AG trimmed its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 0.1% in the first quarter, Holdings Channel.com reports. The firm owned 1,776,576 shares of the company’s stock after selling 1,801 shares during the quarter. Deutsche Bank AG’s holdings in Apellis Pharmaceuticals were worth $38,854,000 as of its most recent SEC […] - 2025-08-13 04:52:53
Mackenzie Financial Corp Grows Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Mackenzie Financial Corp increased its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 14.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 41,533 shares of the company’s stock after purchasing an additional 5,175 shares during the […] - 2025-08-06 05:57:02
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by Assetmark Inc.
Assetmark Inc. boosted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 3,938.7% in the first quarter, HoldingsChannel.com reports. The firm owned 1,252 shares of the company’s stock after acquiring an additional 1,221 shares during the period. Assetmark Inc.’s holdings in Apellis Pharmaceuticals were worth $27,000 as of its most recent filing with […] - 2025-08-06 04:52:49
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $37.00 at JPMorgan Chase & Co.
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its price objective lifted by analysts at JPMorgan Chase & Co. from $35.00 to $37.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 52.89% from the […] - 2025-08-06 03:02:54
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $19.00
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target raised by Royal Bank Of Canada from $17.00 to $19.00 in a research report sent to investors on Friday,Benzinga reports. Royal Bank Of Canada currently has a sector perform rating on the stock. A number of other equities research analysts have also recently commented on […] - 2025-08-04 04:26:49
Citigroup Increases Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $46.00
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target lifted by Citigroup from $41.00 to $46.00 in a report published on Tuesday,Benzinga reports. Citigroup currently has a buy rating on the stock. A number of other brokerages have also weighed in on APLS. Morgan Stanley raised their price objective on shares of Apellis Pharmaceuticals […] - 2025-07-30 04:46:46
Apellis Pharma Secures FDA Approval For EMPAVELI To Treat Rare Kidney Disorders
(RTTNews) - Apellis Pharmaceuticals Inc. (APLS) announced that the U.S. Food and Drug Administration has approved EMPAVELI (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 1 - 2025-07-29 01:03:26
Arizona State Retirement System Lowers Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Arizona State Retirement System cut its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 7.9% in the 1st quarter, HoldingsChannel.com reports. The fund owned 19,539 shares of the company’s stock after selling 1,665 shares during the period. Arizona State Retirement System’s holdings in Apellis Pharmaceuticals were worth $427,000 as of its most recent […] - 2025-07-23 06:58:58
Cerity Partners LLC Boosts Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Cerity Partners LLC increased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 16.7% during the first quarter, Holdings Channel reports. The firm owned 54,444 shares of the company’s stock after acquiring an additional 7,777 shares during the quarter. Cerity Partners LLC’s holdings in Apellis Pharmaceuticals were worth $1,191,000 at the end of […] - 2025-07-23 06:58:56
Diversified Trust Co Takes $282,000 Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Diversified Trust Co purchased a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 12,878 shares of the company’s stock, valued at approximately $282,000. Other hedge funds and other institutional […] - 2025-07-02 05:18:55
Analysts Anticipate IYH To Hit $66
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-23 08:47:36
Analysts Anticipate IYH To Hit $66
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-23 08:47:26
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Acquired by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. lifted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 147.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 74,325 shares of the company’s stock after buying an additional 44,332 shares during the quarter. Assenagon Asset Management S.A.’s […] - 2025-06-18 04:42:57
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stake Lifted by Merit Financial Group LLC
Merit Financial Group LLC increased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 324.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,762 shares of the company’s stock after buying an additional 25,806 shares during the quarter. Merit […] - 2025-06-09 05:46:43
Wealth Enhancement Advisory Services LLC Purchases 19,641 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Wealth Enhancement Advisory Services LLC increased its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 140.8% during the 4th quarter, Holdings Channel reports. The firm owned 33,594 shares of the company’s stock after purchasing an additional 19,641 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Apellis Pharmaceuticals were […] - 2025-06-09 04:48:45
Apellis Pharmaceuticals (NASDAQ:APLS) Trading Up 7.7% on Analyst Upgrade
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) shot up 7.7% during mid-day trading on Monday after Wells Fargo & Company raised their price target on the stock from $26.00 to $29.00. Wells Fargo & Company currently has an equal weight rating on the stock. Apellis Pharmaceuticals traded as high as $18.50 and […] - 2025-06-04 02:01:06
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $29.00
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target increased by Wells Fargo & Company from $26.00 to $29.00 in a research report released on Monday,Benzinga reports. They currently have an equal weight rating on the stock. APLS has been the subject of a number of other reports. Wedbush cut their price objective on […] - 2025-06-03 02:52:45
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 11.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 212,887 shares of the company’s stock after buying an additional 21,822 shares during the quarter. UBS AM a […] - 2025-06-02 05:32:58
14,564 Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Purchased by Vident Advisory LLC
Vident Advisory LLC purchased a new stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 14,564 shares of the company’s stock, valued at approximately $465,000. Several other institutional investors and hedge funds have also recently […] - 2025-05-28 05:31:01
Captrust Financial Advisors Buys Shares of 12,629 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Captrust Financial Advisors purchased a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) during the fourth quarter, Holdings Channel.com reports. The fund purchased 12,629 shares of the company’s stock, valued at approximately $403,000. Several other hedge funds have also made changes to their positions in APLS. Teacher Retirement System of Texas […] - 2025-05-20 04:47:07
Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 52-Week Low on Analyst Downgrade
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) reached a new 52-week low on Wednesday after Mizuho lowered their price target on the stock from $30.00 to $20.00. Mizuho currently has a neutral rating on the stock. Apellis Pharmaceuticals traded as low as $16.61 and last traded at $16.69, with a volume of […] - 2025-05-16 03:00:51
Ameriprise Financial Inc. Boosts Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Ameriprise Financial Inc. boosted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 2.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 882,801 shares of the company’s stock after purchasing an additional 22,507 shares during the period. […] - 2025-05-14 07:10:45
Bank of America Corp DE Has $53.62 Million Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Bank of America Corp DE increased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 72.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,680,213 shares of the company’s stock after purchasing an additional 705,209 shares during the period. Bank of […] - 2025-05-14 06:12:50
The Manufacturers Life Insurance Company Decreases Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
The Manufacturers Life Insurance Company cut its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 13.6% in the fourth quarter, Holdings Channel.com reports. The fund owned 52,897 shares of the company’s stock after selling 8,324 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Apellis Pharmaceuticals were worth $1,688,000 as of […] - 2025-05-12 06:10:47
Apellis Pharmaceuticals (NASDAQ:APLS) Cut to Outperform at Raymond James
Raymond James cut shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) from a strong-buy rating to an outperform rating in a research note released on Friday, MarketBeat reports. They currently have $52.00 price target on the stock, down from their previous price target of $75.00. Other equities research analysts have also issued reports about the […] - 2025-05-12 05:12:48
Robert W. Baird Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $47.00
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective trimmed by Robert W. Baird from $55.00 to $47.00 in a report released on Thursday,Benzinga reports. The firm currently has an outperform rating on the stock. A number of other research analysts have also weighed in on APLS. HC Wainwright reiterated a “buy” rating and […] - 2025-05-11 05:40:50
Apellis Pharmaceuticals (NASDAQ:APLS) Lowered to Neutral Rating by Bank of America
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) was downgraded by investment analysts at Bank of America from a “buy” rating to a “neutral” rating in a research note issued to investors on Friday, Marketbeat Ratings reports. They currently have a $23.00 target price on the stock, down from their previous target price of $41.00. Bank […] - 2025-05-11 05:40:50
Apellis Pharmaceuticals (NASDAQ:APLS) Hits New 52-Week Low Following Weak Earnings
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) hit a new 52-week low during trading on Wednesday following a weaker than expected earnings announcement. The stock traded as low as $16.65 and last traded at $18.78, with a volume of 490307 shares. The stock had previously closed at $19.12. The company reported ($0.74) […] - 2025-05-08 03:08:52
Legal & General Group Plc Sells 10,879 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Legal & General Group Plc decreased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 11.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 86,771 shares of the company’s stock after selling 10,879 shares during the quarter. Legal & General Group Plc […] - 2025-04-24 05:18:56

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc APLS holdings

DateNumber of APLS Shares HeldBase Market Value of APLS SharesLocal Market Value of APLS SharesChange in APLS Shares HeldChange in APLS Base ValueCurrent Price per APLS Share HeldPrevious Price per APLS Share Held
2025-11-12 (Wednesday)9,329APLS holding decreased by -30USD 186,767APLS holding increased by 4173USD 186,767-30USD 4,173 USD 20.02 USD 19.51
2025-11-11 (Tuesday)9,359USD 182,594APLS holding increased by 4773USD 182,5940USD 4,773 USD 19.51 USD 19
2025-11-10 (Monday)9,359USD 177,821APLS holding decreased by -2433USD 177,8210USD -2,433 USD 19 USD 19.26
2025-11-07 (Friday)9,359USD 180,254APLS holding decreased by -4212USD 180,2540USD -4,212 USD 19.26 USD 19.71
2025-11-06 (Thursday)9,359APLS holding decreased by -30USD 184,466APLS holding decreased by -2845USD 184,466-30USD -2,845 USD 19.71 USD 19.95
2025-11-05 (Wednesday)9,389APLS holding decreased by -300USD 187,311APLS holding decreased by -11023USD 187,311-300USD -11,023 USD 19.95 USD 20.47
2025-11-04 (Tuesday)9,689APLS holding decreased by -60USD 198,334APLS holding decreased by -3373USD 198,334-60USD -3,373 USD 20.47 USD 20.69
2025-11-03 (Monday)9,749APLS holding decreased by -60USD 201,707APLS holding decreased by -8892USD 201,707-60USD -8,892 USD 20.69 USD 21.47
2025-10-31 (Friday)9,809USD 210,599APLS holding increased by 7258USD 210,5990USD 7,258 USD 21.47 USD 20.73
2025-10-30 (Thursday)9,809USD 203,341APLS holding decreased by -91419USD 203,3410USD -91,419 USD 20.73 USD 30.05
2025-10-29 (Wednesday)9,809USD 294,760USD 294,7600USD 0 USD 30.05 USD 30.05
2025-10-28 (Tuesday)9,809APLS holding increased by 90USD 294,760APLS holding increased by 5328USD 294,76090USD 5,328 USD 30.05 USD 29.78
2025-10-27 (Monday)9,719USD 289,432APLS holding increased by 15648USD 289,4320USD 15,648 USD 29.78 USD 28.17
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of APLS by Blackrock for IE00B3VWM098

Show aggregate share trades of APLS

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-12SELL-3020.16019.420 19.494USD -585 23.54 Profit of 121 on sale
2025-11-06SELL-3020.12019.530 19.589USD -588 23.63 Profit of 121 on sale
2025-11-05SELL-30020.64019.930 20.001USD -6,000 23.65 Profit of 1,093 on sale
2025-11-04SELL-6020.65019.440 19.561USD -1,174 23.66 Profit of 246 on sale
2025-11-03SELL-6021.41020.120 20.249USD -1,215 23.68 Profit of 206 on sale
2025-10-28BUY9030.05030.480 30.437USD 2,739 23.64
2025-10-24SELL-3028.17028.980 28.899USD -867 23.58 Loss of -160 on sale
2025-10-15BUY18025.22025.390 25.373USD 4,567 23.46
2025-10-02BUY3023.11023.395 23.367USD 701 23.46
2025-09-30BUY6022.63022.990 22.954USD 1,377 23.47
2025-08-21SELL-3027.62027.670 27.665USD -830 23.46 Loss of -126 on sale
2025-07-31BUY9022.34023.560 23.438USD 2,109 23.45
2025-06-30SELL-6017.31017.600 17.571USD -1,054 24.04 Profit of 388 on sale
2025-06-25SELL-3018.39018.610 18.588USD -558 24.16 Profit of 167 on sale
2025-06-20SELL-6017.69018.085 18.045USD -1,083 24.29 Profit of 375 on sale
2025-05-23BUY3017.44017.750 17.719USD 532 25.29
2025-05-19SELL-3017.67017.710 17.706USD -531 25.54 Profit of 235 on sale
2025-05-15SELL-9016.36016.735 16.698USD -1,503 25.69 Profit of 810 on sale
2025-05-12SELL-3017.52018.060 18.006USD -540 25.92 Profit of 237 on sale
2025-05-09SELL-3017.30018.103 18.023USD -541 26.00 Profit of 239 on sale
2025-04-30SELL-3019.21019.210 19.210USD -576 26.45 Profit of 217 on sale
2025-04-24SELL-6017.54017.950 17.909USD -1,075 26.80 Profit of 534 on sale
2025-04-17SELL-3018.20018.550 18.515USD -555 27.27 Profit of 263 on sale
2025-04-15SELL-9018.97019.710 19.636USD -1,767 27.46 Profit of 704 on sale
2025-04-14SELL-9019.33019.670 19.636USD -1,767 27.55 Profit of 712 on sale
2025-04-09SELL-12019.61020.190 20.132USD -2,416 27.83 Profit of 923 on sale
2025-04-07SELL-21019.80019.900 19.890USD -4,177 28.02 Profit of 1,708 on sale
2025-04-04SELL-30019.97023.100 22.787USD -6,836 28.12 Profit of 1,599 on sale
2025-03-31BUY3021.87023.995 23.783USD 713 28.32
2025-03-19SELL-6024.81025.580 25.503USD -1,530 28.76 Profit of 195 on sale
2025-03-14SELL-18024.66024.810 24.795USD -4,463 28.93 Profit of 744 on sale
2025-03-13SELL-6024.37025.275 25.184USD -1,511 28.99 Profit of 228 on sale
2025-03-12SELL-1,02025.18025.910 25.837USD -26,354 29.05 Profit of 3,274 on sale
2025-03-07SELL-6025.04025.490 25.445USD -1,527 29.22 Profit of 226 on sale
2025-03-06SELL-9025.32025.980 25.914USD -2,332 29.28 Profit of 303 on sale
2025-03-03SELL-3024.06025.330 25.203USD -756 29.48 Profit of 128 on sale
2025-02-28SELL-18025.15026.050 25.960USD -4,673 29.55 Profit of 646 on sale
2025-02-26SELL-3026.33028.140 27.959USD -839 29.66 Profit of 51 on sale
2025-02-25SELL-9026.90027.680 27.602USD -2,484 29.71 Profit of 190 on sale
2025-02-18BUY15028.18028.590 28.549USD 4,282 29.90
2025-02-13BUY3027.46028.680 28.558USD 857 30.05
2025-02-12BUY3028.51028.540 28.537USD 856 30.08
2025-02-11BUY9028.53029.140 29.079USD 2,617 30.11
2025-02-06BUY27030.20030.525 30.492USD 8,233 30.16
2025-01-27BUY3029.79030.800 30.699USD 921 30.31
2024-12-30BUY15031.90032.500 32.440USD 4,866 30.17
2024-12-06BUY12033.49034.370 34.282USD 4,114 29.75
2024-12-05BUY3033.45034.230 34.152USD 1,025 29.62
2024-12-04BUY15034.13034.760 34.697USD 5,205 29.46
2024-11-29BUY15033.93034.690 34.614USD 5,192 28.83
2024-11-27BUY12034.14034.400 34.374USD 4,125 28.37
2024-11-26BUY3032.63032.980 32.945USD 988 28.18
2024-11-21BUY15027.75028.140 28.101USD 4,215 27.87
2024-11-20BUY9027.49028.980 28.831USD 2,595 27.89
2024-11-18BUY36026.18026.655 26.608USD 9,579 27.93
2024-11-12BUY24029.26029.605 29.570USD 7,097 27.84
2024-11-08BUY15029.98030.140 30.124USD 4,519 27.69
2024-11-07BUY45028.74029.050 29.019USD 13,059 27.61
2024-11-06BUY6028.83029.990 29.874USD 1,792 27.50
2024-10-31BUY3027.26028.170 28.079USD 842 27.27
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of APLS

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19365,951217673,01554.4%
2025-09-18285,73550519,27055.0%
2025-09-17295,04830,671719,09141.0%
2025-09-16268,0690669,55940.0%
2025-09-15472,44201,211,60639.0%
2025-09-12243,658537571,70242.6%
2025-09-11324,7980885,65536.7%
2025-09-10267,0300588,97445.3%
2025-09-09262,8020694,32637.8%
2025-09-08280,153151,256,01922.3%
2025-09-05470,71601,440,54332.7%
2025-09-04448,9600843,69953.2%
2025-09-03386,35901,028,02937.6%
2025-09-02508,04427892,48656.9%
2025-08-29256,7470579,90944.3%
2025-08-28233,4320526,73244.3%
2025-08-27176,27810583,64630.2%
2025-08-26202,812100448,38945.2%
2025-08-25214,54115390,39855.0%
2025-08-22583,7000847,50268.9%
2025-08-21312,614188498,54462.7%
2025-08-20429,4720902,24747.6%
2025-08-19289,360330683,24842.4%
2025-08-18333,780200651,33751.2%
2025-08-15807,427501,538,25952.5%
2025-08-14935,2731,9511,791,86952.2%
2025-08-131,007,8501,0731,415,03271.2%
2025-08-12517,59819695,02574.5%
2025-08-11211,2720424,91749.7%
2025-08-08328,0630529,05562.0%
2025-08-07515,7050871,95059.1%
2025-08-06419,04112817,33551.3%
2025-08-05541,45001,137,55147.6%
2025-08-04608,18301,365,40744.5%
2025-08-01936,3664,1901,730,76954.1%
2025-07-311,335,9441,7522,982,32644.8%
2025-07-30950,4845,2201,345,39970.6%
2025-07-291,105,2007,8482,166,60551.0%
2025-07-28716,45901,011,53870.8%
2025-07-25286,28252505,61356.6%
2025-07-24396,8641,354663,34559.8%
2025-07-23282,5660473,69059.7%
2025-07-22490,254500749,21565.4%
2025-07-21259,3330398,58265.1%
2025-07-18289,7010501,30557.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.